Lien Vegard Torp, Olberg Dag Erlend, Klaveness Jo, Görbitz Carl Henrik
Department of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0371 Oslo, Norway.
Department of Chemistry, University of Oslo, PO Box 1033 Blindern, N-0315 Oslo, Norway.
Acta Crystallogr E Crystallogr Commun. 2017 Feb 24;73(Pt 3):441-444. doi: 10.1107/S2056989017002948. eCollection 2017 Mar 1.
The protein tubulin is central for maintaining normal cellular processes, and mol-ecules inter-fering with the tubulin dynamics have potential in the treatment of cancerous diseases. The title compound, CHNO, was prepared as a lead compound in a project dedicated to the development of therapeutic agents binding to the colchicine binding site on tubulin, thereby inter-fering with the cell division in cancer cells. It holds many of the main structural characteristics for colchicine binding and has the potential for further modification and functionalization. In the title mol-ecule, the benzene ring is inclined to the quinoline ring by 76.10 (8)°. In the crystal, mol-ecules are linked by two pairs of C-H⋯O hydrogen bonds, forming tubular-like arrangements, propagating along the direction of the diagonals of the plane, and enclosing (26) and (16) ring motifs.
蛋白质微管蛋白对于维持正常细胞过程至关重要，而干扰微管蛋白动力学的分子在癌症治疗方面具有潜力。标题化合物CHNO是在一个致力于开发与微管蛋白上秋水仙碱结合位点结合的治疗剂的项目中制备的先导化合物，从而干扰癌细胞的细胞分裂。它具有许多秋水仙碱结合的主要结构特征，并具有进一步修饰和功能化的潜力。在标题分子中，苯环相对于喹啉环倾斜76.10 (8)°。在晶体中，分子通过两对C-H⋯O氢键相连，形成管状排列，沿平面的对角线方向延伸，并包围(26)和(16)环基序。
